Observational analysis shows nobiletin alleviates gastric injury in vivo and GES-1 cell damage in vitro, indicating potential therapeutic targets ALOX5 and PTGS2.
Nobiletin is one of the citrus polymethoxyflavones and exhibits antioxidant and anti-inflammatory properties. Nobiletin is reportedly used to mitigate ethanol-induced gastric injury and to inhibit Helicobacter pylori infection-related gastric tumorigenesis. The present study aims to elucidate whether and how nobiletin exerts gastroprotective effects in N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced chronic atrophic gastritis (CAG). In MNNG-induced Sprague-Dawley (SD) rats with CAG, we found that nobiletin dose-dependently alleviated MNNG-induced gastric histological lesions, overgeneration of inflammatory cytokines, and intestinal metaplasia. The potential targets of nobiletin in the treatment of CAG were predicted through metabolomic analysis and network pharmacology and subsequently verified by molecular docking and cell experiments. The results demonstrated that nobiletin alleviates MNNG-induced gastric epithelial cell injury and mitochondrial dysfunction by targeting arachidonate 5-lipoxygenase (ALOX5) and prostaglandin-endoperoxide synthase 2 (PTGS2). In conclusion, nobiletin alleviates MNNG-induced gastric injury in vivo and the damage of GES-1 cells in vitro via ALOX5 and PTGS2.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: